about
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody.Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cellsAddition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trialsPrognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.PARP inhibition in castration-resistant prostate cancer.Novel treatment options for refractory Germ Cell Tumours: back to the bench!Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumorBuilding the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
P50
Q30412086-C15AB11E-E2BF-4554-A77A-7CF20FCD1225Q34529351-527140F2-DAF8-447D-9F08-C1FA69926617Q35678417-93BD7838-EA2B-457C-90A1-4A5BF8E1D419Q36230665-1A15E9E4-87EC-42CC-9205-AD4DD37EB459Q37516498-EF7948B3-53EF-47C7-9BD0-82EA987FCC93Q38650264-CAF64228-7D43-401D-B28F-6AD714886E06Q38888805-7915F744-E3C8-47FB-84EE-A60CD91DF5DAQ38903457-8AC292D6-E657-4F34-99A3-7DC7D5E3008BQ38995499-0A017465-0351-425E-B2D8-FA67DAAED314Q39168823-1711892D-BDE8-47D5-83CC-32AC7B3730E4Q39172440-8AAA0FD6-AC9B-4960-A8F7-260870F71C19Q42969284-E316FFBB-300F-4BCD-944F-1E9A30FF50F7Q48246094-45D6CA81-166F-47B9-87BE-B1EAD142C4D4Q52743959-667840E9-0635-4698-A98A-D061B0A4050DQ55021039-9399CC50-D076-43B1-B174-22C837FA7DABQ86836020-6438EBA4-4A18-488A-B845-528C21263457Q89122590-1987E803-8BE0-498A-BF7B-388209B6685B
P50
description
investigador
@es
researcher
@en
name
Lucia Nappi
@en
type
label
Lucia Nappi
@en
prefLabel
Lucia Nappi
@en
P31
P496
0000-0002-4365-7251